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Identification of a novel 
interaction between corticotropin 
releasing hormone (Crh) and 
macroautophagy
Panagiotis Giannogonas1,2, Athanasia Apostolou1,3, Antigoni Manousopoulou4,5, 
Stamatis Theocharis3, Sofia A. Macari4,6, Stelios Psarras7, Spiros D. Garbis4,5,6, 
Charalabos Pothoulakis8 & Katia P. Karalis1,9
In inflammatory bowel disease (IBD), compromised restitution of the epithelial barrier contributes to 
disease severity. Owing to the complexity in the pathogenesis of IBD, a variety of factors have been 
implicated in its progress. In this study, we report a functional interaction between macroautophagy 
and Corticotropin Releasing Hormone (Crh) in the gut. For this purpose we used DSS colitis model on 
Crh −/− or wild-type (wt) with pharmacological inhibition of autophagy. We uncovered sustained 
basal autophagy in the gut of Crh −/− mice, which persisted over the course of DSS administration. 
Autophagy inhibition resulted in partial rescue of Crh −/− mice, while it increased the expression 
of Crh in the wt gut. Similarly, Crh deficiency was associated with sustained activation of base line 
autophagy. In vitro models of amino acid deprivation- and LPS-induced autophagy confirmed the in vivo 
findings. Our results indicate a novel role for Crh in the intestinal epithelium that involves regulation of 
autophagy, while suggesting the complementary action of the two pathways. These data suggest the 
intriguing possibility that targeting Crh stimulation in the intestine may provide a novel therapeutic 
approach to support the integrity of the epithelial barrier and to protect from chronic colitis.
A basic objective of therapeutics is maintenance of tissue homeostasis1. Major obstacles remain for such an objec-
tive in common diseases such as inflammatory bowel disease (IBD), primarily stemming from current gaps to 
its pathogenesis etiology. Genome wide association studies (GWAS) have provided insight on possible distinct 
pathways and mechanisms involved in this regard. IBD has a clear, albeit complicated, genetic background impli-
cating over 150 genes2, whose significant component is linked to innate and adaptive immunity, or to homeo-
static processes such as endoplasmic reticulum or oxidative stress. A consistent finding of GWAS in IBD patients 
confirmed by experimental studies, is the significance of autophagy in the progression of IBD3. Macroautophagy, 
from now on referred as autophagy, is a conserved process across different species that preserves cell survival and 
tissue homeostasis in states of stress by promoting energy availability4,5. Emerging evidence demonstrates the 
contribution of autophagy in a spectrum of human pathological conditions including cancer, infection, inflam-
matory, cardiovascular and neurodegenerative diseases4,6.
At the systemic level, homeostatic regulation is attributed to the coordinated function of the endocrine and 
the autonomic nervous systems7,8. Corticotropin Releasing Hormone/Factor (CRH or CRF) is secreted by the 
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hypothalamus in response to endogenous and external stressors to promote the release of glucocorticoid by the 
adrenals and coordinate the systemic response9–11. Of interest, Crh is also expressed in a number of periph-
eral tissues including the mammalian gut, where it exerts immunomodulatory effects12. Intestinal biopsies from 
patients with IBD identified significantly induced Crh levels compared to control samples, similarly to findings 
from relevant experimental models13–15. In line with the later, Crh-null (Crh −/−) mice show increased suscepti-
bility to the development of acute dextran sodium sulfate (DSS)-induced colitis16. Our working hypothesis is that 
tissue Crh plays a critical role in the maintenance of tissue homeostasis in response to specific challenges such as 
inflammatory stimuli.
Stress has been thought as a major mechanism driving induction of autophagy17. As Crh plays a central role 
in the elicitation of the stress response8, we raised the hypothesis for its putative role in the regulation of auto-
phagy. To investigate this hypothesis, we chose the mouse model of DSS-induced colitis, a disease associated 
with altered autophagy18. In this model, development of colitis is driven by the activation of innate immunity due 
to disruption of the epithelial integrity19,20. Crh −/− mice show increased susceptibility to the development of 
DSS-induced colitis characterized by severely compromised ability to advance to the repair phase16.
This current study examined the possible interaction between Crh and autophagy in the regulation of intes-
tinal inflammation using the DSS model of colitis. The study also examined the possible functional interplay 
between Crh and autophagy in the gut and its effect on the development of severe colitis relative to baseline con-
ditions. Our study demonstrated the close interaction between Crh and autophagy in the progression of colitis 
and repair of the injured epithelium. We also indicate the role of Crh in the induction of autophagy in relevant 
in vitro systems. In total, our study provides clear evidence for the tight interaction between intestinal homeo-
static processes, such as autophagy, and the “stress factor” Crh in the maintenance of the epithelial barrier and its 
restitution following innate immunity-driven colitis.
Results
Altered autophagy activation in the Crh −/− gut. We have previously reported that Crh −/− mice 
show increased susceptibility to the development of DSS colitis and failure to survive the disease for more than 
4 days after the completion of DSS administration16. Compromised autophagy predisposes to the development 
of severe colitis in mice21,22 whereas polymorphisms in autophagy genes have been found in patients with IBD3. 
Here, we assessed the possibility that the severe response of the Crh −/− mice to DSS might be also associated 
with defective activation of autophagy, in line with the role of stress in the activation of colitis17. To address this 
hypothesis, we first assessed the abundance of the autophagosome marker LC3 (isoforms I and II) in Crh −/− 
colonic tissues. LC3 is a ubiquitin-like protein incorporated in the newly forming inner and outer autophagoso-
mal membranes23. The fusion of autophagosomes with endosomes or lysosomes, a central event in autophagy 
activation, is characterized by the rapid degradation of LC3 I to the LC3 II form. Therefore, assessment of the 
lysosomal turnover of LC3 provides a well established measurement of the macroautophagic activity24. We eval-
uated the levels of LC3 II in colonic tissues of wild-type (wt) and Crh −/− mice, seven days after the initiation 
of DSS administration (inflamed state), and four days following the cessation of DSS (repair phase)25 by Western 
blot analysis. Colitis resulted in significant induction of LC3 II formation, which declined as the disease advanced 
towards the repair phase (Fig. 1a). Contrary to our initial hypothesis, we identified increased levels of LC3 II in 
the DSS-treated Crh −/− colonic tissues, as compared to the wt samples, with no evidence for decline over time. 
Further, the Crh −/− mice did not progress to repair ((Fig. 2a–e), a process actively in place, as soon as 4 days 
after completion of the 7 days long DSS treatment. Completion of DSS treatment coincides with the peaking of 
inflammatory activity in both genotypes (Supplementary Figure 1a), significantly increased in the Crh −/− mice 
as we have previously reported16. As shown for the repair phase, in contrast to the active regeneration in the wt 
tissue, H&E analysis of the Crh −/− colon depicted ongoing inflammatory process with minimal evidence of 
repair in the injured epithelium (Fig. 2c), further indicated by the sustained activation of inflammatory markers 
(Supplementary Table 3). As previously reported, the administration of DSS in drinking water induces a colitis 
that is characterized by hematochezia (blood in the stool), body weight loss, mucosal ulceration, and infiltration 
with neutrophil granulocytes25,26. In accordance with the histological features described25, the histopatholog-
ical analysis in our DSS treated groups, reveals focal epithelial erosion with crypt atrophy and diffuse chronic 
inflammatory infiltration, indicative of the induction of DSS colitis. Mucosal damage and inflammatory signs 
are profound in the colonic tissue in both wild-type and Crh −/− mice during the acute phase of DSS-induced 
colitis (7days DSS, Supplementary Figure 1), whereas during the repair phase of colitis only the Crh −/− mice 
continue to exhibit signs of active inflammation (4 days repair, Fig. 2c). Cumulative disease index calculated 
based on edema (scale 0–3), inflammatory indices (scale 0–3) and necrosis (scale 0–3) reflects the impaired repair 
process in the intestinal epithelial barrier associated with Crh deficiency (Fig. 2d). Notably, the increase in LC3 II 
expression in the Crh−/− intestinal tissues was evident even in the non-inflamed tissues (base line), in contrast 
to the almost undetectable expression of LC3 II in the wt tissues. Collectively, these findings suggest that Crh 
participates in the regulation of autophagy in the colon in basal and inflamed states (Fig. 1a,b). We have no evi-
dence that this finding may be associated with altered microbial exposure, since treatment with broad-spectrum 
antibiotics (Supplementary Figure 2b,c) did not normalize the LC3 II immunoreactivity in the Crh −/− tissues. 
Impaired induction of autophagy in the intestine was shown to result in hyperplasia of goblet cells, compromised 
mucus secretion and reduced expression of mucin 2, all hallmark traits for inadequate host defense against invad-
ing microbes27,28. In agreement with the above, we found reduced number and hypoplastic appearance of Goblet 
cells in the Crh −/− colonic samples as compared to the wt tissues (Supplementary Figure 3)28. The constitutive 
activation of autophagy in the Crh −/− mouse gut was also confirmed by immunofluorescence, as use of an 
antibody that recognizes all isoforms of LC3 (Fig. 1b) revealed increase in the characteristic punctuated LC3 
signal in the Crh −/− tissue samples28,29. In line with this observation are the induced proliferation and reduced 
apoptosis in the Crh −/− tissues17 (Fig. 1c,d). The effects of Crh-deficiency in the induction of autophagy are not 
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restricted in the colon, as depicted by the significant increase in the characteristic LC3 punctuate staining in the 
bottom of the Crh −/− small intestine crypts30 (Supplementary Figure 2a). Finally, significantly lower levels of 
phosphorylated Akt in the Crh −/− colon in base line argue for Akt – independent induction of autophagy in 
this case31 (Supplementary Figure 4a,b). Further, no differences were detected between the inflammation-induced 
Akt phosphorylation in the colonic tissues of Crh−/− and wt mice, indicative of the minor contribution, if any, 
of Crh deficiency in this process.
Next, we set up to evaluate the impact of Crh deficiency itself, as opposed to the associated glucocorticoid 
insufficiency of the Crh −/− mice, in the regulation of autophagy. Corticosterone supplementation in the drink-
ing water, 10 μg/ml for 1 week, maintains stable circulating corticosterone close to normal low levels, as we have 
previously shown32. There was no difference in food intake between the wt, Crh −/− and Crh −/− with corti-
costerone supplementation over the course of DSS administration (Fig. 2g,h). Notably, corticosterone adminis-
tration reduced the punctate staining for LC3 of the Crh −/− colon tissue samples (Supplementary Figure 2b,c), 
although its levels remained significantly higher compared to those of the wt colon samples. This finding implies 
Figure 1. Sustained formation of autophagosomes in the Crh −/− gut. (a) Western blot analysis of LC3 I 
and II in whole lysates from colonic tissue of wt and Crh −/− mice in baseline conditions (control), following 
7 days DSS administration and following 4d repair, indicating increased autophagy in the Crh −/− tissue 
(n = 3, 2 individual experiments). (b) Representative immunofluorescence images in colon from wt and Crh 
−/− mice under baseline conditions, following 7 days DSS administration and following 4d repair. Sections 
were stained for LC3 (green) and DAPI (blue). Quantification was performed using the image analysis software 
ImageJ v.1.46r. ***p < 0.001 (n = 6–10, 4 individual experiments) Representative images of colon from TUNEL 
assay (n = 12–14, 2 individual experiments) (c) and BrdU immunofluorescence staining (n = 5, 4 individual 
experiments) (d) from wt and Crh −/− mice under baseline conditions. Quantification is expressed as a 
number of BrdU or TUNEL positive cells per crypt. **p < 0.01, ***p < 0.001 (e) In silico interpretation of 
the proteomic results using the Ingenuity Pathway Analysis software tool showed increased autophagy in the 
intestine of Crh−/− mice compared to WT mice (p-value = 1.29E-7; activation z-score = 2.557). A number of 
autophagy-related proteins (ATGs) were identified, of which ATG3, ATG5, ATG7 and ATG12 were analyzed to 
be up-regulated whereas ATG16L1 down-regulated in the intestine of Crh−/− vs WT mice.
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that locally secreted Crh in the colon has direct impact in controlling the formation of autophagosomes. These 
observations suggest that an increase in baseline autophagy in the Crh −/− gut, may be a mechanistic compo-
nent recruited to overcome potential dysregulation in intestinal function due to compromised Crh expression. 
Interestingly, this adaptation cannot confer protection of the intestinal tissue from any additional superimposed 
stressors, such as DSS (Fig. 2a).
For the unbiased and in-depth evaluation of the Crh deficiency-associated changes to the autophagic “machin-
ery”, we used high-precision global quantitative proteomics with in silico bioinformatics analysis to uncover 
related pathways and networks (Fig. 1e). A total of 6975 proteins were profiled at >95% confidence (q < 0.05) 
(Supplementary Table 1). Of these, 3774 were modulated in the Crh−/− vs. WT intestinal tissue (Supplementary 
Table 2). Bioinformatics interpretation of the modulated proteins using Ingenuity Pathway Analysis showed that 
autophagy was significantly increased in the intestine of Crh−/− vs. WT mice (p-value = 1.29E-7; activation 
z-score = 2.557). Three thousand nine hundred and sixty six (3966) proteins were modulated in the intestine 
of Crh −/− 7d DSS vs. WT 7d DSS mice (Supplementary Table 3) whereas 4299 were differentially expressed 
between WT 7d DSS vs. WT control and Crh −/− 7d DSS vs. Crh −/− control (Supplementary Table 4). 
Validation of this approach was provided by the obtained differences in inflammatory markers, in line with our 
previous studies. As such, myeloperoxidase levels were significantly increased in the intestine of Crh−/− 7d DSS 
vs. WT 7d DSS (Supplementary Figure 1b), whereas a number of cytokines associated with colitis, were expressed 
at higher levels in the intestine of Crh −/− 7d DSS vs. WT 7d DSS mice (Supplementary Table 3). These findings 
Figure 2. Pharmacological inhibition of autophagy (3-methyladenine) in Crh −/− mice during DSS 
administration, prolongs survival and ameliorates the inflammatory response. (a) Kaplan-Meier survival 
curve from wt (n = 53) and Crh −/− (n = 42) administered DSS, and wt (n = 34) and Crh −/− (n = 39) mice 
administered DSS and receiving daily injections of 3-MA during days 1–6 of DSS administration. (b) Body 
weight loss in wt and Crh −/− mice administered DSS, and wt and Crh −/− mice administered DSS and 
receiving daily injections of 3-MA (d1–6) of DSS administration. (c) Representative H&E images from wt 
and Crh −/− colon 4 days after 3% DSS administration (repair) with or without 3MA, depicting the extend 
of epithelial regeneration of the tissue. (d) Cumulative inflammatory index based on edema (scale 0–3), 
inflammatory indices (scale 0–3) and necrosis (scale 0–3), assessed at the completion (7 days) or 4 days after 
(repair) of 3% DSS administration. **p < 0.01, ***p < 0.001 (e) Epithelialization is expressed as a percentage of 
the tissue area covered by crypts at the completion (7 days) or 4 days after (repair) of 3% DSS administration. 
*p < 0.05, **p < 0.01 (f) Cytokines secreted from wt and Crh −/− colonic tissue explants from the indicated 
experimental groups above, isolated at the indicated times following the completion of DSS administration. 
*p < 0.05, ***p < 0.001 Water (g) and food (h) consumption of wt, Crh −/− and Crh −/− mice with 
corticosterone replacement during the course of DSS administration. *p < 0.05.
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are also confirmed by the secreted cytokines from wt and Crh −/− colon explants following 7 days of DSS admin-
istration (Supplementary Figure 1c).
Effects of pharmacological inhibition of autophagy in DSS colitis. Although the impact of deficient 
activation of autophagy in colitis is well documented, there is no prior knowledge on the contribution of sus-
tained activation of autophagy in this disease. We set up to evaluate the possible effect of induced autophagy in the 
progress of DSS colitis, by use of a common, non-specific, autophagy inhibitor 3-Methyladenine (3-MA)33. We 
evaluated two different dosages of 3-MA administered daily in DSS-treated mice, i.e. 10 mg/kg as per a previous 
study34 or 20 mg/kg (~4 mM) that is closer to the maximal recommended dosage of 5 mM, and remained with the 
later due to its reproducible efficacy in this model. Wild-type mice administered DSS and 3-MA worsened the 
disease as shown by increased body weight loss, lethality (34%)35 and IL1 beta (Fig. 2a,b,f). These findings agree 
with the increased susceptibility to colitis of mice with genetic deficiencies in autophagy-related genes28. Notably, 
DSS administered Crh −/− mice treated with 3-MA showed dramatic improvement in survival (50% on day 12 
as opposed to 100% lethality in the vehicle-treated group) (Fig. 2a). As shown, their inflammatory response was 
significantly reduced as shown by the increased formation of new crypts, and reduced edema, cellular infiltra-
tion (Fig. 2c, Supplementary Figure 1a), and locally released TNFalpha and IL1beta36 (Fig. 2f). Thus, the overall 
clinical picture of colitis was indistinguishable between similarly treated wt and Crh −/− mice. These findings 
indicate that in states of Crh deficiency, inhibition of autophagy during colitis prevents the development of severe, 
lethal disease (Fig. 2c) in further support of the dynamic interaction between Crh and autophagy. Building on 
these observations, we assessed the effect of autophagy inhibition during colitis in the regulation of Crh in the 
colon of wt mice. Treatment with 3MA of mice with DSS-induced colitis resulted in further increase of Crh 
immunoreactivity in the inflamed colon (Fig. 3a–c). Crh was particularly expressed in myeloid cells, but not in 
the macrophages (F4/80 positive cells), surrounded by Crh positive cells (white arrows, Supplementary Figure 5). 
Our findings highlight the dynamic regulation of autophagy over the progress of colitis and the need to further 
clarify the specific factors implicated in the epithelial regeneration5.
In vitro confirmation of the interaction between Crh and macroautophagy. To identify the poten-
tial impact of Crh deficiency in autophagy induction beyond the gut we used an in vitro model based on amino 
acid (aa) deprivation of mouse embryonic fibroblasts (MEF). This model relies on starvation, the prototypic 
stimulus, for the induction of autophagy in a very reproducible manner37,38. LC3 II was assessed by western blot 
analysis in wt and Crh −/− MEFs subjected to amino acid deprivation for 4 h. As shown (Fig. 4a), the ratio of 
LC3 II /LC3 I isoforms, both at baseline and following aa deprivation, was significantly increased in the Crh −/−, 
compared to the wt, MEFs. This finding confirms the hypothesis generated by our in vivo findings above, that 
Crh deficiency has direct implications in the regulation of autophagic activity. To further elucidate the effects of 
Crh on autophagy in states of immune activation, we used murine Raw264.7 an in vitro model of LPS-induced 
Figure 3. Autophagy inhibition positive regulates Crh expression and Crh protein levels. (a) Representative 
images from immunohistochemistry in colon from wt mice under baseline conditions (control), following 7 days 
DSS administration and following 4d repair, indicating increased Crh in 3MA-treated mice. Sections were stained 
for Crh (green) and DAPI (blue). (b) Quantitative RT-PCR for mCRH conducted on colon homogenates from wt 
and Crh−/− under baseline conditions (control), during (7d DSS) or 4 days after (4d repair) 3% DSS administration. 
*p < 0.05, **p < 0.01, ***p < 0.001 (c) Western blot analysis of CRH protein levels. Whole protein lysates were 
extracted from wt and Crh −/− colons under baseline conditions (control), during (7d DSS) or 4 days after  
(4d repair) 3% DSS administration with or without 3MA administration.
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autophagy39. Following 16 h of LPS stimulation (1 μg/ml), there is significant induction of LC3 II, abolished by 
co-administration of LPS and Crh (10−7 M) (Fig. 4b). Crh treatment alone had no effect on the constitutive 
activation of LC3 II. Possible reasons for this include the endogenous Crh leading to the maximal possible effect 
in base line autophagy or that Crh is only effective when superimposed to additional challenges, such as the 
LPS-induced immune activation. The latter would be in line with the physiological role of Crh in the control of 
stress-induced responses.
Discussion
Autophagy, a physiological process recruited to maintain cellular energy homeostasis and repair40, is induced by 
starvation and other stressors such as infections and inflammatory diseases, including colitis. Here we studied the 
effect of Crh, a major mediator of the systemic response to stressors, in the regulation of autophagy activation in 
the mouse gut following DSS colitis. Crh exerts immunomodulatory effects both in vivo and in vitro9–11. Crh and 
its receptors are expressed in the intestine of humans and rodents12, in increased abundance during inflammation 
and colitis41,42. Crh deficiency in mice is associated with higher susceptibility to innate immune responses and 
the development of associated colitis. Along these lines, we have previously reported that Crh −/− mice develop 
severe DSS colitis16, in contrast to the protective effects of Crh deficiency in other models of inflammation not 
dependent on innate immunity such as carrageenan43 or TNBS-induced enteritis14. Crh deficiency results in 
glucocorticoid insufficiency, which is normalized by administration of corticosterone in their drinking water44. 
We have previously shown that intestinal Crh deficiency is associated with altered innate immune responses and 
infectious enteritis, independent of their glucocorticoid insufficiency45.
Autophagy is induced to promote cell survival by providing energy, and thus contribute in the maintenance 
of homeostasis4,46. To our surprise, we found sustained activation of autophagy in the Crh −/− mouse colon at 
baseline and its further induction by DSS, as depicted by increased formation of LC3 II (Fig. 1a,b). Sustained 
activation of basal autophagy was only partially corrected by normalization of the corticosterone levels of the 
Crh −/− mice (Supplementary Figure 2b,c), indicating a direct Crh deficiency-dependent effect on autophagy. 
Figure 4. The effect of Crh in the induction of autophagy in vitro. (a) Western blot analysis and quantification 
of LC3 I and II protein levels in whole lysates from wt and Crh −/− MEFs in baseline and following 4 h 
incubation with aminoacid deprived medium. Autophagic activity is induced during aminoacid deprivation, 
as expected, in both wt and Crh −/− MEFs but the ratio of LC3 II/(LC3 I + LC3 II) in Crh −/− MEFs is 
continuously higher than in wt MEFs. *p < 0.05, **p < 0.01, ***p < 0.001 (n = 6, 3 individual experiments) 
(b) Western blot analysis and quantification of LC3 in a model of LPS induced autophagy in Raw264.7 cells. 
Following 16 h of LPS stimulation (1 μg/ml), CRH coadministration (10−7 M) reduces the protein levels of LC3 
II compared to cells treated with LPS alone. *p < 0.05, **p < 0.01 (n = 8, 2 individual experiments).
www.nature.com/scientificreports/
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The inhibitory effects of glucocorticoid on autophagy have been previously reported in other pathophysiological 
settings47.
Our finding of activation of autophagy in the Crh −/− colon was not in line with our hypothesis of compro-
mised autophagy, potentially underlying the severe colitis in the Crh −/− mice. The non-targeted examination 
of the causative agents implicated with this phenomenon using global and in-depth proteomics analysis con-
firmed the association between Crh deficiency and the autophagy pathway in the intestinal tissue. Of interest, 
in contrast to the induced autophagy in the Crh −/− intestinal tissue, Atg16l1 identified by proteomics to be 
significantly down regulated. As previously shown, mice with Atg16l1 gene deletion have resistance to bacterial 
infection-induced enteric disease48, whereas polymorphisms in Atg16l1 are associated with increased susceptibil-
ity to IBD in humans49. These findings raise the hypothesis that Atg16l1 may not be part of the cascade of factors 
driving the induction of autophagy in the Crh −/− gut, modestly surprising given the multimodal regulation of 
this process. Similarly, we show compromised Akt phosphorylation, that is upstream of Atg16l1, in the Crh−/− 
colon in base line (Supplementary Figure 3), in line with the reported Crh – mediated induction of PI3K-Akt50,51. 
The exact level of interaction of Crh and Atg16l1 will be addressed in future studies in primary cells genetically 
engineered to carry the polymorphism associated with IBD or not.
Blockade of autophagy via administration of 3-MA rescued around 50% of the Crh −/− mice from detri-
mental colitis. Notably, the progress of DSS colitis was similar between wt mice treated with 3-MA, and Crh 
−/− non- 3-MA treated mice, based on the increased lethality during the repair phase. These data support the 
hypothesis that autophagy is necessary to support mucosal repair and regeneration following injury, possibly by 
recycling the dying cells’ catabolism products. Defects in this process may drive additional immune activation 
that interferes with proper development of the newly formed crypts promoting the chronicity, rather than the 
resolution of inflammation52. These results agree with studies in mice with mutations in autophagy genes that 
develop severe colitis21,22. Similar mutations were found by genome-wide association studies (GWAS) in IBD 
patients highlighting the significance of proper activation of autophagy in the pathogenesis of colitis3. The severe 
colitis in the Crh −/− mice, or in the wt mice with blockade of autophagy, and the significant amelioration of coli-
tis in Crh −/− mice treated with 3MA, indicate a dynamic interplay between the pathways driving the activation 
of Crh and autophagy in the intestinal epithelia. Notably, optimal regulation of colitis occurred in the presence 
or absence of both mechanisms, suggesting their cooperation is instrumental to keep in balance both the active 
and the resolution phases of colitis. This data highlights the complex, time- and inflammation-phase dependent 
regulation of autophagy induction while they provide evidence for the contribution of additional tissue expressed 
factors in this process.
Finally, the findings with the starvation-induced autophagy in MEFs37,38 (Fig. 4a) demonstrate the impact of 
Crh deficiency in LC3 II regulation beyond the intestinal tissue. Further, Crh blocked the LPS induced autophagy 
in the RAW murine line of macrophages, a model of innate immune activation39 (Fig. 4b). A number of reports 
have shown induction of autophagy in macrophages following LPS-activation of TLR4 signaling39,53,54 or simply, 
exposure to proinflammatory cytokines, such as TNFalpha and IL1beta55,56. The inhibitory effects of Crh in this 
process could also underlie the significantly lower LPS-induced IL1 activation in the Crh −/− macrophages 
and other tissues57,58. Collectively, our current findings suggest that Crh and autophagy operate primarily via 
non-overlapping, complementary pathways to regulate the development and the outcome of DSS-induced colitis. 
Furthermore, these data raise the possibility that Crh operates as a brake for the sustained activation of autophagy, 
an effect in line with its role in the adaptive response to stressors.
In summary, here we describe a missing function of the stress hormone Crh in the regulation of autophagy 
activation. We present evidence that this effect is linked to maintenance of gut homeostasis under basal condi-
tions, as shown by our findings in Crh deficient mice. Our data from the DSS colitis uncover the contribution of 
tissue Crh in the regulation of innate immunity-induced autophagy activation, similar to its HPA axis-mediated 
effects in the systemic adaptation to stressors59,60. Future studies are required to address the potential beneficial 
effects of Crh agonists in the support of epithelial restitution in IBD, and other intestinal diseases. These studies 
may contribute in the ongoing efforts for identification of small molecules targeting tissue-specific activation of 
autophagy for a spectrum of therapeutic applications60.
Materials and Methods
Animals and animal care. wt and Crh −/− male mice of 129xC57BL/6 genetic background, weighing 
25–30 g and aged 10–12 wks were used in this study. Animal housing and care was performed according to 
NIH guidelines; all experimental procedures were approved by the Animal Care and Use Committee of Boston 
Children’s Hospital, and of BRFAA in Athens, Greece. The animals were housed under controlled conditions 
(temperature 22 °C; 12 h light/dark cycle; lights on at 7 am) and were given free access to standard laboratory 
pellet formula and tap water. Daily inspection of cages for food spillage and monitoring of body weight and food 
intake was done for the duration of the study.
DSS colitis. Mice (n = 5–10/group, four independent cohorts) were given 3% DSS (M.W. = 36,000–
50,000 kDa; MP Biomedicals) in their drinking water for 7 days. To study the repair phase following colitis, the 
DSS solution was replaced with clean water for 4 days. Mice were evaluated twice/day for signs of moribund 
state, diarrhea and rectal bleeding. At day 3 or 7 post-DSS administration, or as described in the Results, the 
mouse colon was excised, and segments of the transverse colon (1 cm) were fixed in 4% paraformaldehyde (PFA) 
and processed for hematoxylin and eosin (H&E) staining. For the autophagy inhibition experiments, 20 mg/kg 
3-methyladenine (3MA, M9281, Sigma) in w.f.i., was administered daily (day1–6) by intraperitoneal injections. 
Vehicle (w.f.i.)-injected wt and Crh −/− mice served as controls.
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Corticosterone replacement. Corticosterone (27840, Sigma) was added in the drinking water at final con-
centration of 10 μg/ml for 1 week, replaced with fresh solution every 2 days.
Histological analysis. Colons were fixed in 4% PFA and embedded in paraffin. Blocks were serially sec-
tioned vertical to the axis of the lumen. For H&E and Alcian Blue/PAS stainings, tissues were processed according 
to standard protocols. The histologic severity of colitis was graded in a “blinded” fashion by a pathologist blinded 
to samples’ identity, on a 0–3 ascending scale. Cumulative inflammatory index, a descriptive term, represents the 
average score of each section following characterization and rating for based on edema, inflammatory cells and 
necrosis in most affected regions. For the goblet cells characterization, well longitudinally sectioned crypts were 
selected and examined by counting the number of Alcian Blue/PAS stained cells along the crypt and expressed as 
number of goblet cells per crypt. The size of goblet cells was determined by randomly selecting 100 Alcian Blue/
PAS stained cells per condition and the area was measured with ImageJ v1.46 software.
Cytokine measurement. Intestinal tissue segments (2 cm) from the descending colon were collected from 
all experimental groups, and incubated for 24 hours in RPMI medium supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin/streptomycin. The cultures were incubated at 37 °C in a humidified 95% O2/5% CO2 
atmosphere. At the end of each culture period, the supernatants were collected and stored at −80 °C until they 
were assayed. Quantification of secreted cytokines was performed using ELISA kits (Ready-Set-Go!® ELISA, 
eBioscience) according to manufacturer’s instructions.
Quantitative proteomics. Colon from WT mice (n = 6), Crh− /− mice (n = 6), WT mice after 7 days 
exposure to DSS (n = 6) and Crh− /− mice after 7 days exposure to DSS (n = 6) were dissolved in 200 μL of 
0.5 M triethylammonium bicarbonate, 0.05% sodium dodecyl sulfate and homogenised using the FastPrep® -24 
Instrument (MP Biomedicals, Santa Ana, CA, USA). Lysates were subjected to pulsed probe sonication (Misonix, 
Farmingdale, NY, USA) and centrifuged (16,000 g, 10 min, 4 °C). The supernatant was measured for its protein 
content using the Direct DetectTM system (Merck Millipore, Darmstadt, Germany). From each lysate, 33.3 μg 
of protein was pooled to form two biological replicates for each of the four conditions (WT, Crh−/−, WT 7d 
DSS, Crh−/− 7d DSS). Lysates were then subjected to reduction, alkylation, trypsin proteolysis, 8-plex iTRAQ 
labeling and two-dimensional liquid chromatography, tandem mass spectrometry analysis as described previ-
ously61–64. The unprocessed raw data files were submitted to Proteome Discoverer 1.4 for target decoy search-
ing with SequestHT as reported61–64. Quantification ratios were median-normalized and log2 transformed. The 
threshold of percent co-isolation excluding peptides from quantification was set at 30. A one-group T-Test was 
performed to identify proteins that were modulated in the intestine from Crh −/− vs. WT and Crh −/− 7d DSS 
vs. WT 7d DSS mice. A two-group T-Test was performed to identify proteins that were differentially expressed 
between WT 7d DSS vs. WT control and Crh −/− 7d DSS vs. Crh −/− control. A p-value ≤ 0.05 was considered 
significant. Proteomics data were deposited to the ProteomeXchange Consortium via the PRIDE partner reposi-
tory (dataset identifier PXD002886).
The Diseases and Functions feature of the Ingenuity Pathway Analysis software tool (http://www.ingenu-
ity.com) was used to identify biological processes significantly over-represented in the modulated proteome. 
P-values ≤ 0.05 were considered significant.
Western blot. Western blot analysis was performed by standard methodology. Antibodies against LC3 
(1:1000, PM036, MBL), phospho-Akt (1:1000, 4060P, Cell Signaling), total-Akt (1:1000, 9272, Cell Signaling), 
CRH (1:500, NBP1-35703, NOVUS Biologicals) and GAPDH (1:20.000, AM4300, Ambion) were commercially 
available.
Immunofluorescence staining. Paraffin embedded sections of intestine from wt and Crh−/− mice were 
processed according to the manufacturer’s protocol. Briefly, sections were deparaffinized, washed and antigen 
retrieved with 10 mM citrate buffer (pH 6.3). The tissues were then washed, covered with blocking buffer (20 mM 
HEPES, 1% bovine serum albumin (BSA), 135 mM NaCl) for 5 minutes and incubated overnight with the pri-
mary antibody (LC3, 1:2000, PM036, MBL; Crh, 1:100, NBP1-35703, Novus Biologicals; F4/80, 1:100, ab6640, 
Abcam; CD11b, 1:50, 553307, BD Pharmingen) diluted in blocking buffer. For BrdU immunohistochemistry 
(1:50 anti-BrdU antibody, ab6326, Abcam), following antigen retrieval, sections were sequentially incubated in 
2N HCl for 30 minutes at 37 °C, in 0.1 M borate buffer for 10 min and in blocking solution (10% Normal Goat 
Serum). Finally, sections were washed and incubated with a secondary antibody (1:500 Alexa Fluor® 488 Goat 
Anti – rabbit IgG, Invitrogen) and mounted with VECTASHIELD® Mounting Medium with DAPI (H-1200, 
Vector Laboratories). F4/80/CD11b
BrdU labeling and TUNEL assay. 5-Bromo-2′ -deoxyuridine (BrdU, B5002, Sigma Aldrich) uptake exper-
iments were done by intraperitoneal injection (100 μg/g body weight) of nucleotides into mice for 3 hours before 
sacrifice. Tissues of BrdU-injected mice were processed for paraffin embedding. Subsequently, 5 μm sections were 
used for immunohistochemistry.
TUNEL assay was performed on 5 μm paraffin sections using DeadEnd™ Fluorometric TUNEL System 
(G3250, Promega) following the manufacturer’s instructions.
Semi quantitative real-time PCR. RNA was extracted from colonic tissue using TRI reagent (Sigma). 
cDNA was made from 2 ug total RNA with MMLV reverse transcriptase and random hexamer primers (Life 
Technologies Inc., Rockville, MD, USA). PCR products from semi quantitative real-time PCR with primers for 
CRH (forward primer: 5′ - CGC AGC CCT TGA ATT TCT TG -3′ , reverse primer: 5′ - GCG GGA CTT CTG 
TTG AGA TT -3′ ) were detected with SYBR Green (Molecular Probes, Life Technologies) on an ABI PRISM 
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7000 Sequence Detection System (Applied Biosystems). Real-time qPCR data were converted to linear data by 
calculating 2-ΔCt values for 18S normalized data.
Cell lines and cultures. Mouse embryonic fibroblasts (MEFs) were isolated by female wt and Crh −/− mice, 
when embryos were 13.5–14.5 days old as previously described64. Isolated fibroblasts were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin and 1% 
L-glutamine. For the aminoacid deprivation experiments, cells were incubated for 4 h with a special formulation 
of Invitrogen DMEM-12320. RAW264.7 cells were maintained in Dulbecco’s modified Eagle’s medium containing 
10% FBS. For LPS induced autophagy experiments, RAW264.7 cells were treated with LPS (1 μg/ml, L2630, Sigma 
Aldrich), Crh (10−7M, C3042, Sigma Aldrich) or both.
Statistical Analysis. Results are expressed as mean ± SEM. Data was analyzed by two-tailed, unpaired, 
equal variance student’s t-test, one-way ANOVA followed by Bonferroni’s post hoc multiple comparison tests, 
or repeated measures ANOVA, as appropriate, using GraphPad Prism, version 5.00 (GraphPad Software Inc.).
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